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junctional epidermolysis bullosaEpidermolysis bullosa (EB) is a rare, inherited blistering genodermatosis. Patients with junctional EB (JEB)
due to LAMB3mutations havewidespread blisters and erosions of skin, mucosae, and nails, creating signif-
icant physical, emotional, and psychosocial burdens. Here we report the use of colchicine for ameliorating
hypergranulatingwounds in a 41-year-old femalewith JEB generalized intermediate. Her skinwounds and
granulation tissue gradually exacerbated under silicone dressings such that she becameprofoundly anemic.
Subsequently, she was commenced on colchicine 500 μg daily on the basis that it may inhibit cell prolifer-
ation and be anti-inﬂammatory. After a 6-month trial of colchicine, she had an objective and subjective im-
provement in her validated EB Disease Activity and Scarring Index activity and damage scores and Quality
Of Life in EB score with less skin erosions, granulation tissue, and erythema. In addition, her anemia re-
solved. She denied any gastrointestinal side effects. The exact mechanism of colchicine in assisting reduc-
tion of the blistering, erosions, and granulation in JEB is unclear, but the anti-inﬂammatory and
antimitotic properties of colchicine may be partially responsible for this process.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Epidermolysis bullosa (EB) is a rare, inherited blistering
genodermatosis. The hallmark feature of EB is extreme skin fragility
and recurrent vesiculobullous eruptions following mild mechanical
injury. Based on the level within which blisters arise, EB is divided
into 4 major subtypes named EB simplex (EBS), junctional EB (JEB),
dystrophic EB (DEB), and Kindler syndrome caused by 18 different
gene mutations (Fine et al., 2014). Patients with more severe types
of EB such as JEB and recessive dystrophic EB (RDEB) have more
widespread blisters and erosions. JEB generalized intermediate, for-
merly known as JEB non-Herlitz, follows an autosomal recessive pat-
tern and is characterized by decreased laminin-332 or collagen XVII
staining (Fine et al., 2014). Chronic cutaneous inﬂammation and ero-
sions with bleeding are responsible for anemia of chronic disease
(Hwang et al., 2015); iron deﬁciency anemia; severe burning pain;
malnutrition; and recurrent cutaneous infections for these individ-
uals, creating signiﬁcant physical, emotional, and psychosocial bur-
dens. So far, there are no treatments that reverse the manifestations
of EB. Protection of EB wounds is aimed at addressing the symptomsll).
er Inc. on behalf of Women'sand preventing further trauma and secondary bacterial infections
using nonstick dressings. Here, we report a case of JEB that demon-
strated a dramatic response to colchicine.Case report
The patient was a 41-year-old Caucasian female with JEB general-
ized intermediate (EB-registry #14) caused by two different LAMB3
mutations (R635X/1588delAG) and who had been generally well,
with two full-term pregnancies (Nakano et al., 2002). She had suc-
cessfully given birth to two unaffected children (Choi et al., 2011).
Prior to the establishment of the National EB Dressing Scheme in
Australia in 2009 for funding of dressings, she could not afford sili-
cone nonstick dressings and only used gentian violet on her erosions,
air dried after a bath, without dressings and had only a limited num-
ber of erosions, which were well controlled. After June 2010, she
began using silicone dressings (Mepilex, Mepitel, Mepilex Lite, and
Mepilex Transfer) under the scheme as recommended by the EB
nurse at the scheme. Subsequently, she gradually developed exuber-
ant granulation tissue under the dressings, and her skin failed to
adapt to the changes, despite several different nonstick silicone–
based dressings being tried. At various times, weaning of theseDermatologic Society. This is an open access article under the CC BY license
57M. Kim et al. / International Journal of Women's Dermatology 2 (2016) 56–59dressings was attempted, but the granulation tissue did not heal as
before with the gentian violet and stuck to her clothes.
Over the last 2 years, she developedmultifactorial anemia (hemo-
globin fell in from 122 g/L in February 2013 to 89 g/L in February
2014) resulting from iron deﬁciency and chronic inﬂammation,
weight loss, and nutritional deﬁciency. She hadmultiple blood trans-
fusions for the severe anemia, which kept recurring within a few
weeks, and skin infections with methicillin sensitive staphylococcusFig. 1. Clinical response to colchicine. a) Before using silicone dressings. Multiple skin
erosions painted with gentian violet. No surrounding erythema or inﬂammation.
b) Before the commencement of colchicine. Signiﬁcant skin erosions with granulation
tissue, surrounding erythema and inﬂammation. c) After taking colchicine for 6 months.
Clinical improvement with fewer erosions and granulation tissue and erythema.aureus and Group B streptococcus requiring 4 units of packed red
blood cell transfusion, iron infusion, and long-term intravenous anti-
biotic administration. She was investigated with upper endoscopy,
colonoscopy, and a pill-cam study without an identiﬁable source of
bleeding as the hemoglobin dropped more precipitously than previ-
ously. Hemolytic screen was also negative. It was concluded that
her anemia most likely resulted from chronic inﬂammation of her
skin, marked cutaneous erosions, and iron deﬁciency.
Despite having regular bleach and salt baths to prevent recurrent
skin infections, she suffered from recurrent skin infections requiring
repeated courses of antibiotics. In October 2014, she developed
acute renal failure and delirium during one of these episodes of sep-
sis, from which she recovered. The decision was made to trial 500 μg
oral colchicine on the basis that it might inhibit cell proliferation and
reduce inﬂammation. It took 6 months of persuasion for her to agree
to try it. Baseline laboratoryworkwas performed, including complete
blood count, electrolytes, urea, creatinine, liver function test, and C-
reactive protein (CRP).
In our EB clinics, patients are routinely monitored using validated
EB-speciﬁc outcome measures, the EB Disease Activity and Scarring
Index (EBDASI) and the Quality of Life in EB (QOLEB) questionnaire.
The EBDASI distinguishes activity scores separately from damage.
The total activity score is 276, and a total damage score is 230 (Loh
et al., 2014). The total score for the QOLEB is 51, and a lower score
on the QOLEB correlates with the better quality of life (Frew et al.,
2009). Her scores had been monitored during the previous year at
each of her visits.
Three monthly blood testing was performed to monitor serologi-
cal response to colchicine. This patient was followed up at 3 months
during the 6-month period of colchicine therapy. Full skin examina-
tion was performed, each time with a complete removal of all the
dressings in the designated EB bathroom. She felt symptomatically
better after starting colchicine, with less stinging and burning sensa-
tion of the skin. She denied having gastrointestinal symptoms such as
nausea, vomiting, or diarrhea. Clinically, there were fewer skin ero-
sions and granulation tissue and erythema (Fig. 1, a–c). Her EBDASI
score improved from 106 total (30 for activity and 76 for damage)
at the baseline to 60 (23 for activity and 37) for damage after 6
months of colchicine treatment (Fig. 2). Her quality of life score,
which had graduallyworsened over the preceding few years, also im-
proved from 35/51 to 24/51 after the 6 months of colchicine treat-
ment (Fig. 3). Blood studies did not reveal any rare hematological
side effects, including agranulocytosis, thrombocytopenia, and
aplastic anemia. Renal function remained stable, and her hemoglobin
improved signiﬁcantly from 95 g/L at the baseline to 128 g/L after the
6 months. A steady decline of her elevated CRP level was also ob-
served (Table 1).
Discussion
Patients with JEB and some with recessive DEB have exuberant
cutaneous granulation tissue resulting from repetitive phases of
wound healing, including inﬂammation, re-epithelization, angiogen-
esis, and tissue remodeling. As mentioned in this case, a number of
complicationsmay arise from chronic erosions and inﬂammation. Ac-
cording to the US National EB Registry population, death from sepsis
was more frequently seen in severe types of EB including JEB and
RDEB. The cumulative risk of death from sepsis by age 60 was the
highest, at 35.4%, in JEB non-Herlitz subtypes (Fine, 2009). Frequent
hospitalizations, impaired wound healing, bacterial colonization of
chronic nonhealing skin wounds, and recurrent use of topical and
oral broad-spectrum antibiotics predispose these patients to sepsis
with more resistant microorganisms. The prevalence of anemia in
JEB and RDEB was much higher, at 68.8% and 68.0%, respectively,
compared to that of EBS at 11.3% (Hwang et al., 2015).
Fig. 2. Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) score with the pink area indicating the duration of colchicine intake. Improved EBDASI total score from
106 at the baseline to 60. EBDASI activity score improved from 30 to 23. EBDASI damage score improved from 76 to 37.
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inﬂammation, blood loss through skin wounds, and compromised
bone marrow response to the elevated levels of erythropoietin. The
onset of these problems after commencement of silicone-based dress-
ings in this patient is concerning. There has been no randomized con-
trolled trial to compare the efﬁcacy and safety of these types of
dressings in EBwithmore traditional nonstick dressings, such as Jelonet
or Vaseline gauze. Silicone dressings when used for other con-
ditions are usually left in place for up to a week for localized
wounds. However, in EB, particularly in humid environmentsFig. 3.Quality of Life in Epidermolysis Bullosa (QOLEB) scorewith the purple area indicating
35/51 at baseline to 24/51 after 6 months of colchicine treatment.such as Australia, dressings need to be changed every 1 to 2
days to avoid the excess colonization of bacteria in wounds
that occurs under occlusive dressings. The dressings are not
cut to ﬁt exactly into the wounds. They are square dressings,
and the patients’ normal skin as well as the wound bed is in con-
tactwith the silicone surface. This particular patient has always taken
baths on a daily basis and continued to do so evenwhen the dressings
were applied, because she did not like the odor under the dressings.
Colchicine is an alkaloid extracted from the plant Colchicum
antumnale (Bibas et al., 2005). Anton Von Störck ﬁrst used colchicinethe duration of colchicine intake. Improved quality of life evident by QOLEB scores from
Table 1
Blood parameters (colchicine commenced in November 2014). No evidence of hematological side effects. Improvement of hemoglobin with a steady decline in CRP.
Parameters Oct 10, 2014 Oct 28, 2014 Nov 19, 2014 Feb 18, 2015 July 13, 2015 Normal range
Hb (g/L) 78 104 95 111 128 115-165
Platelets 459 443 492 432 550 150-450
WBCs 6.1 7.1 6.9 9.6 10.9 4-11
MCV 78 83 85 87 89 80-97
CRP 202.1 N/A 150.3 42.1 47.3 b3
CRP, C-reactive protein; Hb, hemoglobin; MCV, mean corpuscular volume; WBCs, white blood cells.
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is well known for its antimitotic and anti-inﬂammatory properties. It
interferes with microtubule formation by forming high-afﬁnity com-
plexeswith dimers of tubulin and subsequently inhibiting the transfor-
mation of tubulin into microtubules. It is also thought to increase the
activity of collagenase and decrease collagen production. For this rea-
son, colchicine has been tried as an adjuvant therapy for treating keloid
scars in small case studies and has shown some beneﬁt (Singler, 2010).
Colchicine has been the standard treatment for gouty ﬂares
for some time. It is also widely used for the treatment of amy-
loidosis associated with familial Mediterranean fever. In derma-
tology, colchicine has been used in treating a number of
neutrophilic dermatoses, including Sweet’s syndrome, dermati-
tis herpetiformis, psoriasis, and Behçet’s disease (Bibas et al.,
2005).
Colchicine has also been used for some bullous and ulcerative dis-
orders including EB acquisita (EBA) and ulcerative necrobiosis
lipoidica (Cunningham et al., 1996; Schoﬁeld and Sladden, 2012).
Cunningham et al. used colchicine in 4 patients with EBA refractory
to conventional therapy and observed reduced blister formation
and skin fragility. The study postulated that the neutrophil inﬁltrate
in early EBA initiating the inﬂammatory cascade may have been re-
tarded by colchicine by interfering with polymorphonuclear chemo-
taxis. Another case study reported on a patientwith a 10-year history
of bilateral ulcerative necrobiosis lipoidica on the shins who experi-
enced a complete resolution after taking colchicine for 2 months
(Schoﬁeld and Sladden, 2012). It was thought that colchicine may
work bymodulating inﬂammatory responses by inhibiting tumor ne-
crosis factor alpha and the nuclear factor-kB signaling pathway.
Granulation tissue in JEB consists of collections of mononuclear in-
ﬂammatory cells, macrophages, neutrophils, and cellular debris.
Hence, this aberrant manifestation of wound healing may have
been reduced. Colchicine was tested in cultured explants from pa-
tients with EB simplex and DEB but not JEB, demonstrating an in-
crease in collagenase expression (Bauer and Tabas, 1987).
Conclusion
Use of colchicine to treat inﬂammation in EBwounds has not been
reported in the literature, to our knowledge. The antimitotic and anti-
inﬂammatory properties of colchicine suggest it has a potential rolein JEB. Here we report a case where colchicine has improved skin
healing, reduced skin inﬂammation, and improved anemic complica-
tions related to JEB. In addition, the extent of use of silicone based
dressings for patients with limited junctional EB may need to be
reviewed, particularly when they are applied to the normal skin
around the wound for protection.
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